Facebook Twitter LinkedIn Google Plus RSS

Alvogen acquires rights to pain medication with $58M in 2012 sales

By ,

Global generic pharmaceuticals company Alvogen, with its U.S. base in the Pine Brook section of Montville Township, announced today it has acquired U.S. commercialization rights for a controlled-release pain killer from Florham Park-based Shionogi Inc.

According to the announcement, the nonsteroidal anti-inflammatory Naprelan is manufactured in controlled-release tablets at dosages of 375 mg, 500 mg and 750 mg. The product will be marketed by Almatica Pharma Inc., a subsidiary of Alvogen. In a separate transaction, Alvogen also acquired all rights and interest in the new drug application to the U.S. Food and Drug Administration for Naprelan from Pa.-based Stat-Trade Inc.

Financial terms of the transaction were not disclosed, but Naprelan had annual U.S. sales of $58 million in 2012, the company said in a statement.

The company announced Darren Alkins as its new president in October.

Also Popular on NJBIZ

Write to the Editorial Department at editorial@njbiz.com

Related Stories

Leave a Comment


Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy


Subscribe to Our Newsletters!
Click Here to Subscribe for Free Now!